Showing papers by "David A. Gewirtz published in 2004"

TL;DR: These studies suggest that ATZ has the capacity to interfere with topoisomerase I in the tumor cell, a function not evident in cis-platinum-based drugs.

TL;DR: It is suggested that the nature of the cellular response to methotrexate depends, in large part, on p53 and caspase function, and that the senescence phenotype may occur in the absence of direct DNA damage.

TL;DR: Data indicate that EB 1089 (and 1alpha, 25 dihydroxycholecalciferol or its analogs) could selectively enhance breast tumor cell sensitivity to radiation through the promotion of cell death, in part through the generation of ceramide and the suppression of polo-like kinase.